HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Characterization of anticancer properties of 2,6-diisopropylphenol-docosahexaenoate and analogues in breast cancer cells.

Abstract
The present study describes the characterization and evaluation of novel anticancer conjugates, 2,6-diisopropylphenol-docosahexaenoate (PP-DHA), and its analogues including 2,4-diisopropylphenol-docosahexaenoate (DIPP-DHA), 2-isopropylphenol-docosahexaenoate (IPP-DHA), 2-cyclohexanephenol-docosahexaenoate (CHP-DHA) and phenol-docosahexaenoate (P-DHA) on breast cancer cell lines. Representative breast cancer cell lines, based on estrogen alpha receptor (ER) and oncogene Her-2 expression, were used and include MDA-MB-231 (ER-negative, Her-2-negative), MCF-7 (ER-positive, Her-2-negative) AU565 (ER-negative, Her-2-positive) and MDA-MB-361 (ER-positive, Her-2-positive). The PP-DHA conjugate significantly inhibited cell growth and induced cell loss in the breast cancer cell lines similarly; however, this conjugate was not effective against normal mammary epithelial cells. The effect of various conjugates were in PP-DHA>IPP-DHA>DIPP-DHA>CHP-DHA>>P-DHA order. PP-DHA and IPP-DHA conjugates were stable in human and mouse serum. Furthermore, the non-hydrolyzable amide-linked conjugate analogues affected breast cancer cells in a manner similar to that of the ester-linked conjugates. This suggests that ester-linked PP-DHA and IPP-DHA conjugates were stable during treatment to breast cancer cells due to structural hindrance. PP-DHA did not affect PPARalpha or PPARgamma activities but its anticancer effects appear to be mediated in part though the inhibition of histone deacetylase (HDAC) activity. Further experiments are needed to confirm their molecular target and to test the effectiveness of these compounds in an in vivo model for their anticancer properties. In conclusion, these results suggest that the novel PP-DHA and IPP-DHA conjugates and their amide derivatives may be useful for the treatment of breast cancer.
AuthorsKevin A Harvey, Zhidong Xu, Phillip Whitley, V Jo Davisson, Rafat A Siddiqui
JournalBioorganic & medicinal chemistry (Bioorg Med Chem) Vol. 18 Issue 5 Pg. 1866-74 (Mar 01 2010) ISSN: 1464-3391 [Electronic] England
PMID20153203 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright 2010 Elsevier Ltd. All rights reserved.
Chemical References
  • 2,6-diisopropylphenol docosahexaenoate
  • Antineoplastic Agents, Hormonal
  • Estrogen Receptor alpha
  • Docosahexaenoic Acids
  • Receptor, ErbB-2
  • Histone Deacetylases
  • Propofol
Topics
  • Animals
  • Antineoplastic Agents, Hormonal (chemical synthesis, chemistry, therapeutic use)
  • Breast Neoplasms (drug therapy)
  • Cell Line, Tumor
  • Docosahexaenoic Acids (chemical synthesis, chemistry, therapeutic use)
  • Estrogen Receptor alpha (metabolism)
  • Female
  • Histone Deacetylases (chemistry, metabolism)
  • Humans
  • Mice
  • Propofol (chemistry)
  • Receptor, ErbB-2 (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: